

Supplementary Table S 1. *BRCA1* and *BRCA2* promoter methylation by pyrosequencing

ID number	BRCA1 (% met)	U/M	BRCA2 (% met)	U/M
1	6.53	U	4.37	U
2	10.8	U	8.5	U
3	6.93	U	2.7	U
4	0	U	0	U
5	65.4	M	4.9	U
6	2.4	U	1.53	U
7	5	U	7.17	U
8	6.3	U	0	U
9	4.33	U	4.57	U
10	8.23	U	3.83	U
11	3.87	U	4	U
12	7.6	U	7.57	U
13	3.1	U	4.23	U
14	4.73	U	2.57	U
15	0	U	3.73	U
16	3.83	U	3.63	U
17	0	U	6.4	U
18	80.23	M	0	U
19	4.43	U	3.03	U
20	91.47	M	3.9	U
21	4.4	U	3.27	U
22	3.6	U	5.23	U
23	58.53	M	2.5	U
24	4.1	U	5.27	U
25	30.63	M	3.57	U
26	9.77	U	4	U
27	42.2	M	3.2	U
28	5.23	U	4.32	U
29	55.47	M	10	U
30	23.68	M	4.28	U
31	10	U	5.3	U
32	34.03	M	4	U
33	5.8	U	4	U
34	52.37	M	4.33	U
35	0	U	0	U
36	5.97	U	3	U
37	0	U	0	U
38	0	U	ne	ne
39	6.47	U	4.2	U
40	35.87	M	5.73	U
41	5.97	U	5.13	U
42	9.23	U	0	U
43	6.1	U	5.2	U
44	5.8	U	4.73	U
45	5.9	U	3.77	U

ID number	BRCA1 (% met)	U/M	BRCA2 (% met)	U/M
-----------	------------------	-----	------------------	-----



46	8	U	3.57	U
47	0	U	0	U
48	14	U	3.4	U
49	4.2	U	34.31	M
50	5.8	U	10	U
51	3.77	U	3.3	U
52	7.33	U	58.3	M
53	6.43	U	0	U
54	31.07	M	0	U
55	7.5	U	10	U
56	20.73	M	ne	ne
57	64.77	M	4.1	U
58	0	U	44.07	M
59	6.1	U	5.6	U
60	5.47	U	3.4	U
61	ne	ne	ne	ne
62	12	U	U	u
63	11	U	7.1	U
64	6.53	U	3.33	U
65	8.73	U	0	U
66	65.63	M	4.13	U
67	7.23	U	6.13	U
68	5.33	U	3.67	U
69	4.2	U	0	U
70	5.73	U	3.13	U
71	9.73	U	10.16	U
72	4.3	U	9.7	U
73	0	U	U	U
74	42.07	M	46.6	M
75	8	U	4.83	U
76	3.57	U	3.27	U
77	4.6	U	4.27	U
78	0	U	3.57	U
79	4.33	U	3.4	U
80	ne	ne	ne	ne
81	4.83	U	4.43	U
82	49.47	M	2.77	U
83	3.37	U	5.37	U
84	6.5	U	2.4	U
85	8	U	6.57	U
86	6.83	U	2.9	U
87	10	U	10	U
88	0	U	3.33	U
89	7.43	U	2.87	U
90	5.33	U	2.23	U

Legend. M, methylated; U, unmethylated; ne, not evaluable. Percentages represent the average of all methylation values at Individual CpG sites investigated in BRCA1 and BRCA2 promoter. Genomic coordinates of all CpG sites are specified in Figure 1. All analyses have been performed in duplicate



Supplementary Table S2. Primers and PCR conditions of pyrosequencing analysis.


Gene		Primers	AT (°C)	Amplicon lenght (bp)
BRCA1	M3-F	AGGTTAGAGGGTAGGTATTTATGG		105bp
	M3-R ^{biotin}	ACTCTAAATTAAACCACCCAATCT	56	
	<i>M3-Seq</i>	ATGGTAAATTAGGTAGAATTTTT		
	M4-F	ATTTAGTATTTGAGAGGTTGTTGTT		150bp
	M4-R ^{biotin}	AAAACCCCACAACCTATCC	56	
	<i>M4-Seq</i>	TTTGAGAGGTTGTTGTTA		
BRCA2	M1-F	GTTAGTGGTGGTAGTG		106bp
	M1-R ^{biotin}	AACCTTTCTCTCAAACATAAATAAAAAATTA	56	
	<i>M1-Seq</i>	GTTTTTAGTACTTTAGTTAG		
	M4-F	GGAGTAGTTGTTGATTGT		149bp
	M4-R ^{biotin}	TCACAAATCTATCCCCTCAC	TD (61-58)	
	<i>M4-Seq</i>	GGAGTAGTTGTTGATTGTT		

Legend: F, forward primer; R, reverse primer; Seq, sequencing primer; AT, annealing temperature; bp, base pair; TD, touch down

Supplementary Table S3. Inter-experiments variability and definition of the limit of blank , LoB

Test	Unmethylated samples mean±SD	Unmethylated samples mean+3SD	Methylated samples (mean±SD)
BRCA1 MET3	0.73%±1.41	4.96%	91.23%±6.74
BRCA1 MET4	0.5%±0.98	3.44%	76.3%±8.4
BRCA2 MET1	2.31%±2.59	10%	83.53%±7
BRCA2 MET4	0.4%±1.13	3.8%	95.22%±3.35

Fully unmethylated samples were tested in 10 different runs and the results were recorded to perform LoB calculation (LoB is the highest analyte concentration expected to be found when replicates of a blank sample containing no analyte are tested). We set the LoB for all methylation tests at a value of 10%, corresponding to the mean value plus three standard deviations of 10 independent measures.



Supplementary Figure S1. To set-up the methylation tests we analyzed artificial control samples at different percentages of DNA methylation (0%, 10%, 50%, 100%) by appropriately mixing commercial fully methylated DNA and fully unmethylated DNA (Human WGA Methylated & Non-methylated DNA Set, Zymo Research). Data from three independent amplification and pyrosequencing experiments of these four samples demonstrated that methylation tests are able to quantify the presence of methylated cytosines with a good linearity. Two assays for each gene have been set up. On X- and Y-axes methylation levels (%) are reported.